This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Acadia Q1 Earnings Beat, Nuplazid & Daybue Sales Drive Revenue Growth
by Zacks Equity Research
ACAD reports encouraging first-quarter results as earnings and revenues beat estimates, driven by year-over-year growth in Nuplazid and Daybue sales.
BEAM Stock Down 19% as Q1 Earnings & Revenues Miss Estimates
by Zacks Equity Research
Beam Therapeutics incurs a wider-than-expected loss in the first quarter. The company remains focused on pipeline development.
Krystal Biotech Q1 Earnings and Sales Miss Estimates, Stock Down
by Zacks Equity Research
KRYS reports disappointing first-quarter 2025 results, with both earnings and sales missing estimates. Shares down.
Zoetis Q1 Earnings & Revenues Beat Estimates, '25 Outlook Raised
by Zacks Equity Research
ZTS reports better-than-expected first-quarter results as earnings and revenues surpass estimates. Management raises 2025 guidance.
RXRX Stock Down 17% as Q1 Earnings & Revenues Miss Estimates
by Zacks Equity Research
Recursion Pharmaceuticals stock falls due to weaker-than-expected first-quarter results, along with the abandonment of certain key pipeline programs.
Beam Therapeutics Inc. (BEAM) Reports Q1 Loss, Misses Revenue Estimates
by Zacks Equity Research
Beam Therapeutics (BEAM) delivered earnings and revenue surprises of -11.71% and 51.29%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?
FOLD Q1 Earnings and Sales Miss Estimates, Stock Falls
by Zacks Equity Research
Amicus' first-quarter 2025 earnings and sales miss estimates. Shares decline.
Blueprint Medicines Stock Up Despite Lower-Than-Expected Q1 Earnings
by Zacks Equity Research
BMPC's first-quarter earnings and sales miss estimates. However, shares rally on raised Ayvakit sales guidance for 2025.
Alkermes' Q1 Earnings and Revenues Fall Short of Estimates
by Zacks Equity Research
ALKS' earnings and revenues lag first-quarter 2025 estimates. Sales of proprietary products surpass management's expectations.
Agios' Q1 Loss Narrower Than Expected, Revenues Lag Estimates
by Zacks Equity Research
AGIO's earnings beat estimates in the first quarter of 2025, while revenues miss the same.
Madrigal Q1 Earnings Beat, MASH Drug Sales Drive Top Line, Stock Up
by Zacks Equity Research
MDGL stock is rising as it reports better-than-expected first-quarter results, beating earnings and revenue estimates, driven by strong Rezdiffra sales.
Bausch Health Q1 Earnings and Revenues Miss Estimates, Stock Down
by Zacks Equity Research
BHCs first-quarter 2025 adjusted earnings and revenues miss estimates. Salix performs lower than expected. Stock declines.
UTHR Q1 Earnings & Revenues Beat Estimates on Higher Tyvaso Sales
by Zacks Equity Research
United Therapeutics reports better-than-expected first-quarter 2025 results, beating both earnings and revenue estimates, driven mainly by strong Tyvaso sales.
Sage Therapeutics' Q1 Earnings Miss Mark, Revenue Rise Y/Y
by Zacks Equity Research
SAGE's earnings and revenues miss estimates in the first quarter of 2025. The company focuses on the commercialization of its depression drug Zurzuvae.
Repligen's Q1 Earnings Beat Estimates, Revenues Surge Y/Y
by Zacks Equity Research
RGEN reports better-than-expected first-quarter results. The company increases its total revenue (on a reported basis) guidance for 2025.
Beam Therapeutics to Report Q1 Earnings: What's in the Cards?
by Zacks Equity Research
In the absence of any marketed drugs, investors are set to focus on BEAM's pipeline updates when it reports first-quarter 2025 earnings.
Beam Therapeutics (BEAM) Moves 12.6% Higher: Will This Strength Last?
by Zacks Equity Research
Beam Therapeutics (BEAM) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into further price increase in the near term.
The Zacks Analyst Blog Highlights Illumina, BEAM, Twist Bioscience, Wave Life Sciences and CRISPR Therapeutics
by Zacks Equity Research
Illumina, BEAM, Twist Bioscience, Wave Life Sciences and CRISPR Therapeutics are part of the Zacks top Analyst Blog
Promising Genomics & Synthetic Biology Stocks to Consider in 2025
by Ekta Bagri
Investors interested in the Genomics and Synthetic Biology theme should consider these stocks: Twist Bioscience Corporation, Wave Life Sciences, and CRISPR Therapeutics AG.
BEAM's IND for BEAM-302 in Genetic Disorder Study Gets FDA Clearance
by Zacks Equity Research
The FDA clears Beam Therapeutics' investigational new drug application for BEAM-302 for the treatment of alpha-1 antitrypsin deficiency in the United States.
Beam Therapeutics (BEAM) Down 21.4% Since Last Earnings Report: Can It Rebound?
by Zacks Equity Research
Beam Therapeutics (BEAM) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
CRISPR Therapeutics Stock Trades Near 52-Week Low: Time to Buy or Sell?
by Sundeep Ganoria
The fall in CRSP stock can be attributed to a lack of pipeline updates. Despite securing approval for its first marketed product in early 2024, it is yet to record product sales.
BEAM Down Despite Positive Initial Data From Genetic Disorder Study
by Zacks Equity Research
Beam Therapeutics posts positive initial data from a phase I/II study investigating BEAM-302 for treating alpha-1 antitrypsin deficiency.
Madrigal Q4 Earnings Beat, MASH Drug Sales Drive Top Line, Stock Up
by Zacks Equity Research
MDGL stock is rising as it reports better-than-expected fourth-quarter results, beating earnings and revenue estimates, driven by strong Rezdiffra sales.
Beam Therapeutics' Q4 Earnings & Revenues Beat Estimates
by Zacks Equity Research
BEAM incurs a narrower-than-expected loss in the fourth quarter. The company remains focused on pipeline development.